AOI Nagpur performs two consecutive successful bone marrow transplants

Innovative bloodless autologous transplants offer new hope for multiple myeloma patients enhancing cancer care accessibility in Central India

0
38
New Delhi: The American Oncology Institute (AOI) at Nangia Specialty Hospital, Nagpur, has successfully performed two consecutive bloodless autologous bone marrow transplants for multiple myeloma (MM) patients. These patients, a 58-year-old male from Amravati and a 57-year-old male from Madhya Pradesh underwent the procedure using their own stem cells, significantly reducing the risk of infection and rejection.
Dr. Shailesh Bamborde, a Bone Marrow Transplant (BMT) Specialist, led the medical team in these transformative treatments. The autologous approach, which utilizes the patient’s own cells, has proven effective in enhancing recovery and ensuring long-term positive outcomes.
AOI Nagpur has made these advanced medical services accessible and affordable, particularly benefiting patients in the Vidarbha region of Maharashtra and Central India. Harish Trivedi, CEO of CTSI – South Asia, highlighted, “AOI Nagpur’s achievement in bloodless bone marrow transplants marks a significant in advancing healthcare accessibility in Central India. This innovation underscores their commitment to delivering high-quality care and reducing healthcare disparities in the region.”
Multiple myeloma, a common type of blood cancer arising from plasma cells in the bone marrow, accounts for 10-15% of blood cancers. It presents symptoms such as renal failure, anemia, bone pain, infections, and fatigue. AOI Nagpur’s innovative bloodless transplant technique offers new hope for effective treatment and improved quality of life for patients.
Dr. Amit Dhawan, Regional Chief Operating Officer of AOI Nagpur, emphasized, “AOI Nagpur is dedicated to offering world-class medical care with compassion and affordability. Our recent success in bloodless bone marrow transplants signifies our capability to provide cutting-edge treatments locally, reducing the burden on patients and their families.”
Dr. Shailesh Bamborde underscored, “The treatment of multiple myeloma has evolved remarkably in the last few decades. Improved understanding of myeloma biology has led to significant advances in diagnosis, prognosis, and response assessment. These advances have led to very impressive improvements in the survival rates of myeloma patients. With our bloodless autologous transplant approach, we use the patient’s own stem cells to rejuvenate their marrow, minimizing risks and optimizing recovery. This method not only ensures safety but also improves long-term outcomes for our patients.”
The BMT and Hematology Unit at AOI Nangia Specialty Hospital offers comprehensive care for various blood disorders and cancers, including leukemia, lymphoma, myeloma, and anemias. AOI’s multidisciplinary approach integrates medical oncology, hemato-oncology, radiation oncology, and surgical oncology services, adhering to international standards of cancer treatment.